OriC-321

N/A

Report date: 2022/07/20 13:12:14

Base Information

Drug NameOriC-321
Drug Alias NameBMCA and GPRC5D dual target CAR-T cellsOriC-321Ori-C-321
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-GPRC5DAnti-BCMA
TargetsG-protein coupled receptor family C group 5member DB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang UniversityOriCell Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOriCell Therapeutics Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A